Best Western Hotel & Conference Center
5625 O'Donnell Street
Baltimore, Maryland 21224-4630, USA (map)
November 5, 2008
9:00am to 6:00pm
Dr Suresh V. Ambudkar (National Cancer Institute, NIH) and Abcam, Inc.
The meeting will cover multidrug resistance in cancer and ABC transporters: basic, clinical, regulation and drug-drug interaction aspects.
- Keynote: Dr Michael M. Gottesman (National Cancer Institute, NIH)
Current status of multidrug resistance and ABC transporters
- Dr Suresh V. Ambudkar (National Cancer Institute)
Mechanism of action of multidrug resistance-linked ABC drug transporters
- Dr David S. Miller (National Institute of Environmental Health Sciences, NIH)
Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier
- Dr. Robert B. Innis (National Institute of Mental Health, NIH)
Positron emission tomographic imaging of drug efflux transporters
- Dr Gilbert J. Burckart (U.S. Food and Drug Administration)
Drug-drug interactions and regulatory implications for membrane transporter substrates in drug development
- Dr Maria R. Baer (University of Maryland Greenebaum Cancer Center)
Clinical and therapeutic implications of multidrug resistance-associated ABC drug transporters
Additional talks from submitted abstracts:
- Dr. Wilfred Stein (National Cancer Institute, NIH)
Polymorphisms within PfMDR1 alter the substrate specificity for antimalarial drugs in Plasmodium falciparum
- Ms. Maria DeRosa (Hospital for Sick Children)
Inhibition of MDR1 as possible therapy for Fabry Disease
- Dr. Zhe-Sheng (Jason) Chen (St. John's University)
Tyrosine kinase inhibitors as modulators of multidrug resistance in cancer
- Dr. Robert Robey (National Cancer Institute, NIH)
Novel inhibitors of ABCG2 identified by high-throughput screening analysis
- Dr. Demian Park (Phylonix)
Zebrafish: A predictive model for assessing modulators of P-glycoprotein efflux
- Dr. Anne-Marie Bleau (Memorial Slaon-Kettering Cancer Center)
Loss of PTEN increases ABCG2 activity in glioma tumor stem cells and contributes to the MDR phenotype
- Dr. Daotai Nie (Southern Illinois University School of Medicine)
The role of PXR in cancer multidrug resistance
- Dr. Tianyong Zhao (University of Kentucky)
Multidrug resistance-associated protein 1 (MRP1) localizes in junction of cultured HL1 cells and mediates doxorubicin induced stress signal transmission between cells
Full program also available as pdf download.
Welcome and introduction to scope of the meeting - Dr. Suresh Ambudkar
Keynote speaker: Dr. Michael Gottesman - Current status of MDR and ABC transporters
Dr. Suresh Ambudkar - Mechanism of action of MDR-linked ABC drug transporters
Dr. Robert Innis - Positron emission Tomographic imaging of drug efflux transporters
Dr. David Miller - Regulation of P-glycoprotein and other ABC drug transporters at the bloodbrain barrier
Dr. Demian Park - Zebrafish: A predictive model for assessing modulators of P-glycoprotein efflux
Dr. Zhe-Sheng (Jason) Chen - Tyrosine kinase inhibitors as modulators of multidrug resistance in cancer
Dr. Maria Baer - Polymorphisms within PfMDR1 alter the substrate specificity for antimalarial drugs in Plasmodium falciparum
Dr. Maria Baer - Clinical and therapeutic implications of multidrug resistance-associated ABC drug transporters
Ms. Maria Fabiana De Rosa - Inhibition of MDR1 as possible therapy for Fabry Disease
Dr. Daotai Nie - The role of PXR in cancer multidrug resistance
Dr. Gilbert Burckart - Drug-drug interactions and regulatory implications for membrane transporter substrates in drug development
Dr. Anne-Marie Bleau - Loss of PTEN increases ABCG2 activity in glioma tumor stem cells and contributes to the MDR phenotype
Dr. Robert Robey - Novel Inhibitors of ABCG2 identified by high-throughput screening analysis
Dr. Tian-Yong Zhao - Multidrug resistance-associated protein 1 (MRP1) localizes in junction of cultured HL1 cells and mediates doxorubicin induced stress signal transmission between cells
Reception and poster session
Posters will be judged. The winner will receive up to $150 off their registration for a future Abcam conference or an antibody from the Abcam catalog.
Posters must be no larger than four feet tall by eight feel wide.
The registration fee includes lunch, coffee, reception, and abstract book.
Students are categorized as those in full-time education at the time of registering. Proof of student status may be requested.
If you are paying via American Express, please contact Katie via email or at 617-577-4263 since we cannot take the cards online at the moment.
Abcam is proud to have the following companies exhibiting at the meeting.
Absorption Systems® is “the drug absorption company”. A preclinical ADME contract research organization, we are also developing a suite of proprietary human cell lines, CellPort Technologies™ for the definitive identification and characterization of drug-transporter interactions. These models are used in the bidirectional transport assay format the FDA requires for submission.
Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and standardized testing, including forensic human identification, paternity testing and food testing.
Please contact the Best Western Hotel & Conference Center to see if rooms are still available.
Parking at the Best Western is complimentary if you are attending the meeting.
If you are interested in sponsoring or exhibiting at this meeting, please contact us for more information.
Download the flier for the meeting. (Warning - large file)
Feel free to print it out and distribute it at your organization.
For more information:
Katie Sedat, Abcam Events Team